Physiological role and source
The endogenous growth factor is proteinaceous in nature and belongs to glycoproteins. The bulk of the substance (90%) is synthesized in the peritubular cells of the kidneys, while the remaining 10% is produced by liver cells. The main triggering mechanism or trigger factor for a sharp increase in the production of endogenous erythropoietin is tissue hypoxia. In chronic kidney diseases, this natural synthesis drops significantly, creating a need for medical intervention.
Mechanism of action at the cellular level
The action of the substance is aimed at stimulating the formation of new red blood cells:
- The active substance finds and binds to high-affinity receptors (EpoR) located on the membranes of immature erythroid cells.
- Stimulation of proliferation and differentiation of progenitor cells is initiated.
- The natural release of reticulocytes directly into the bloodstream from the bone marrow is accelerated.
Pharmacology and indications
For therapeutic use, recombinant products created by genetic engineering methods as complete analogues of human erythropoietin are used. The main representatives of the group include epoetin alfa and epoetin beta.
The drugs are administered parenterally — subcutaneously or intravenously, and the dosage is calculated in IU per kilogram of body weight. The main indications are various types of anemia:
- Anemia in chronic renal failure (CRF).
- Bone marrow pathologies and malignant tumors.
- Chronic inflammatory processes and AIDS.
- Anemia in premature infants.
Dynamics of the effect and safety
The therapeutic response develops gradually:
- The first clinical results are noticeable after 1–2 weeks from the start of the course.
- Full normalization of hematopoiesis parameters is observed after 8–12 weeks.
The use of these agents requires safety monitoring due to potential side effects:
- Cardiovascular system: increase in blood pressure, hypertensive crises, thrombosis, chest pain, and edema.
- Nervous system (usually against the background of blood pressure surges or encephalopathy): severe headaches, dizziness, confusion, and seizures.
Class and exam questions
Where in the body is the bulk of endogenous erythropoietin synthesized?
The main source (90%) is peritubular cells of the kidneys, with another 10% produced by liver cells.
What is the main triggering factor that sharply increases the synthesis of this substance?
Erythropoietin synthesis increases sharply in response to the development of tissue hypoxia.
What are the main neurological side effects of therapy?
Headache, dizziness, confusion, and seizures may occur against the background of elevated blood pressure or encephalopathy.
What else to study on this topic
- Test on the nature of the substance: choice between steroids, polypeptides, glycoproteins, and glycolipids
- Classification question on the origin of recombinant products compared to monoclonal antibodies
- Differential diagnosis of indications in CRF and other types of renal failure
- Specifics of calculating dosage in IU/kg during parenteral administration
- Review of the timeframe from the start of application to the normalization of hematopoiesis
Master the entire topic in the «Pharmacology» course
This is a summary. The course covers everything tested in classes and exams.
- Complete study guide on "Erythropoietin products" and 5,304 more pages of the subject
- Assignments and quizzes after every topic — just like in a colloquium
- AI tutor answers questions on the topic anytime
- 116 video lessons on the subject
Other topics in the section "Hematopoietic Agents"
Free video lessons: pharmacologyShort lessons with study notes — no registration required.
Prepared by WhiteCoat Pro faculty in accordance with the medical school curriculum. For educational purposes only.